Oncolytic Virus (Seprehvir™, Seprehvec™)
Oncolytic Immunotherapies
Sorrento's oncolytic viral vector assets ishanduro yakagadziridzwa yeyakajairika human herpes simplex virus (HSV-1). Seprehvir yakagadzirwa nekugona kunyatsoparadza masero ebundu ukuwo ichikurudzira anti-tumor murwere mhinduro dzemuviri. Sechikamu chechirongwa chayo chekusimudzira kiriniki yepasi rose, Seprehvir yakapihwa kune vanopfuura zana varwere vakuru nevana mumhando dzakasiyana dzemamota akasimba anosanganisira glioblastoma, mesothelioma, melanoma, gomarara remusoro nemutsipa, sarcoma yevana uye neuroblastomas yevana.
Mukana wakakosha weSeprehvir, kana uchienzaniswa nemamwe eHSV-based oncolytic therapies, nderekuti yakapihwa zvakachengetedzeka mutsinga, intratumorally uye neloco-regional infusion kuti igadzirise kurapa kugomarara remurwere.
Iyo Seprehvec asset ipurojekiti yechizvarwa cheramangwana ine chinangwa chekupa dzimwe nzira dzekurapa uye inogona kukurumidza kugadzira novel oncolytic immunotherapies:
- "Targeted" kunyanya kune mamwe marudzi emamota masero
- "Kushongedzerwa" nemamwe majini ekuwedzera kuparadzwa kwebundu masero
- Yakawanda-inoshanda "yakanangwa" uye "yakashongedzerwa" akasiyana ane inowedzerwa kuuraya masero uye immuno-stimulatory zviitiko.